---
title: 'Industry Daily Summary: What Happened on November 17, 2026'
headline: J&J agrees to pay $2.2 billion upfront for Ollin’s eye drugs
description: Lilly added a mutant-calreticulin antibody to its pipeline, while Seawolf
  paired $100 million in funding with a Sanofi licensing deal.
url: https://thebench.bio/news/industry/2026-11-17
topic: industry
date: '2026-11-17'
covers:
- '2026-11-17'
date_published: '2026-11-17T12:04:07Z'
date_modified: '2026-11-17T12:04:07Z'
tags:
- Industry
- Funding
- Agriculture
sources: 7
publisher: TheBench.Bio
---

# Industry Daily Summary: What Happened on November 17, 2026

**J&J agrees to pay $2.2 billion upfront for Ollin’s eye drugs**

Lilly added a mutant-calreticulin antibody to its pipeline, while Seawolf paired $100 million in funding with a Sanofi licensing deal.

## Today in brief

Johnson & Johnson will acquire Ollin Biosciences for $2.2 billion upfront, gaining a late-stage retinal drug and another antibody program. [1] [2] Eli Lilly will acquire Calytrix Bio in a deal worth as much as $1.5 billion, most of it contingent on clinical and regulatory milestones. [3]

Seawolf Therapeutics emerged from stealth with $100 million in financing and a Sanofi partnership that could generate as much as $1.2 billion in milestone payments. [4]

## J&J adds Ollin’s late-stage retinal drug

Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront, plus as much as $1.125 billion in regulatory and commercial milestones. [1] [2] The deal includes OLN324, a bispecific antibody in Phase III development for wet age-related macular degeneration and diabetic macular edema. [1] [5]

OLN324 targets VEGF and Ang2, the same pathways targeted by Roche’s Vabysmo. [1] [2] Ollin reported that, in a Phase 1b comparison, OLN324 produced faster and greater structural changes and numerically greater vision improvement than Vabysmo at 20 weeks. [2] The results come from an early-stage study. J&J will take responsibility for the pivotal trials. [2]

Blackstone Life Sciences will provide as much as $750 million for Phase III development in return for potential milestones and royalties. [1] [2] The acquisition also includes OLN102, an investigational antibody for thyroid eye disorder. [2] The companies expect the deal to close by year-end. [2]

## Lilly buys Calytrix for a mutant-calreticulin antibody

Eli Lilly agreed to acquire Calytrix Bio in a transaction worth as much as $1.5 billion, including an upfront payment and further payments tied to clinical and regulatory milestones. [3] Calytrix’s investigational antibody is designed to target Type 1 and Type 2 mutant calreticulin on tumor cells. [3]

Calytrix says the approach is intended to remove mutant cells while sparing healthy tissue and normal blood-cell production. [3] The company is developing the program for essential thrombocythemia and myelofibrosis, two blood disorders. [3] J.P. Morgan Life Sciences Private Capital established Calytrix in 2025. [3]

## Seawolf pairs $100 million financing with Sanofi deal

Seawolf Therapeutics emerged from stealth with $100 million in seed and Series A financing and an exclusive licensing partnership with Sanofi. [4] The collaboration will research treatments for bleeding disorders and other undisclosed indications. [4] Milestone payments for research, development, and commercial progress could total as much as $1.2 billion, with royalties also possible for Seawolf. [4]

Seawolf’s TRIDENT platform uses lipid nanoparticles to carry DNA into cell nuclei, aiming to support production of a therapeutic protein. [4] The company says its nonviral system may allow repeat dosing. Seawolf reported proof of concept in preclinical mouse and nonhuman-primate models. [4] Seawolf is also advancing an internal program for metabolic diseases. [4]

## Also worth knowing

- Cellectis plans to cut as much as 70% of its workforce in 2026 and 2027 after ending two clinical-stage CAR-T programs, shifting resources to two preclinical gene-editing programs. [6]
- AstraZeneca acquired Omniose, its US research partner, for an undisclosed amount to support preclinical vaccine programs against serious bacterial infections. [6]
- More than 100 UK bio-based-industry stakeholders urged the government to back domestic manufacturing and commercialization, warning that research benefits could move overseas. [7]

## The day in numbers

- **$2.2 billion**: J&J’s upfront payment to acquire Ollin, before potential milestones. [1] [2]
- **$1.5 billion**: Maximum stated value of Lilly’s acquisition of Calytrix, including milestone payments. [3]
- **$100 million**: Funding Seawolf raised as it emerged from stealth. [4]

## Also published

- [UK sets 2029 timeline to end Palantir's NHS contract](<https://pharmaphorum.com/news/uk-sets-2029-timeline-end-palantirs-nhs-contract>), pharmaphorum
- [Why clarity matters as much as access in healthcare](<https://pharmaphorum.com/patients/why-clarity-matters-much-access-healthcare>), pharmaphorum
- [The Compound Effect: Real-World Evidence for the Impact of Company-Led Medical Education](<https://pharmaphorum.com/oncology/compound-effect-real-world-evidence-impact-company-led-medical-education>), pharmaphorum
- [Biotech’s boardroom gains for women fail to translate to CEO roles](<https://www.biospace.com/business/biotechs-boardroom-gains-for-women-fail-to-translate-to-ceo-roles>), BioSpace
- [J&J’s $2B NewCo buy, neoantigen vaccines, Overton odds — a BioCentury podcast](<https://www.biocentury.com/article/661638/j-j-s-2b-newco-buy-neoantigen-vaccines-overton-odds-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rss>), BioCentury
- [Pair of Lilly deals includes takeout of stealthy Calytrix for up to $1.5B: Deals Report](<https://www.biocentury.com/article/661629/pair-of-lilly-deals-includes-takeout-of-stealthy-calytrix-for-up-to-1-5b-deals-report?utm_source=bc_rss&utm_medium=rss>), BioCentury
- [J&J bets $2.2B on Ollin’s vision loss drug](<https://www.biopharmadive.com/news/Johnson-johnson-ollin-acquire-ophthalmology-vegf-ang2-drugs/874728/>), BioPharma Dive
- [Deals Roundup: J&J Buys Ollin, Lilly Adds Calytrix, and Novartis and Sanofi Strike Platform Pacts](<https://www.biopharminternational.com/view/deals-roundup-j-j-buys-ollin-lilly-adds-calytrix-and-novartis-and-sanofi-strike-platform-pacts>), BioPharm International
- [J&J cuts $3.3bn deal to buy eye drug developer Ollin](<https://pharmaphorum.com/news/jj-cuts-33bn-deal-buy-eye-drug-developer-ollin>), pharmaphorum
- [Lilly strikes again, buying Calytrix in $1.5bn deal](<https://pharmaphorum.com/news/lilly-strikes-again-buying-calytrix-15bn-deal>), pharmaphorum
- [Lilly adds to buyout streak with $1.5B purchase of startup Calytrix](<https://www.biopharmadive.com/news/lilly-calytrix-bio-acquire-deal-myelofibrosis-essential-thrombocythemiaenial-/874719/>), BioPharma Dive
- [STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues](<https://www.statnews.com/2026/11/16/versant-lilly-put-100-million-behind-new-startup-aimed-at-solving-one-of-gene-therapys-thorniest-issues/?utm_campaign=rss>), STAT Biotech
- [Big-name investors pour $100M into DNA therapeutics developer Seawolf](<https://www.biopharmadive.com/news/seawolf-therapeutics-dna-versant-startup-financing/874465/>), BioPharma Dive

## Sources

1. [J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences](<https://www.pharmaceutical-technology.com/news/jj-outlays-up-to-3-3bn-to-buy-ophthalmology-specialist-ollin-biosciences/>), Pharmaceutical Technology, 2026-11-16
2. [J&J’s $2.2B Ollin Buyout Brings Late-Stage Eye Drug; Blackstone Deal Adds Trial Funding](<https://medcitynews.com/2026/11/johnson-johnson-jnj-ollin-biosciences-acquisition-bispecific-antibody-vegf-ang2-wet-amd-dme/>), MedCity News, 2026-11-16
3. [Lilly agrees to acquire Calytrix Bio for $1.5bn](<https://www.pharmaceutical-technology.com/news/lilly-to-acquire-calytrix-bio-1-5bn/>), Pharmaceutical Technology, 2026-11-17
4. [Seawolf Therapeutics and Sanofi agree $1.2bn drug deal](<https://www.pharmaceutical-technology.com/news/seawolf-sanofi-agree-drug-deal/>), Pharmaceutical Technology, 2026-11-17
5. [After gene therapy setbacks, J&J  pays $2.2B for Ollin, adds retinal disease candidate](<https://www.biocentury.com/article/661621/after-gene-therapy-setbacks-j-j-pays-2-2b-for-ollin-adds-retinal-disease-candidate?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-11-16
6. [Cellectis plans 70% workforce cuts; Sanofi signs $1.2B DNA medicines deal; AstraZeneca buys Omniose](<https://european-biotechnology.com/latest-news/cellectis-plans-70-workforce-cuts-sanofi-signs-1-2b-dna-medicines-deal-astrazeneca-buys-omniose/>), European Biotechnology, 2026-11-17
7. [UK biotech sector calls on government to support sector’s growth on home soil](<https://www.pharmaceutical-technology.com/news/uk-biotech-sectors-calls-on-government-support-sector-scale/>), Pharmaceutical Technology, 2026-11-17

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.pharmaceutical-technology.com/news/jj-outlays-up-to-3-3bn-to-buy-ophthalmology-specialist-ollin-biosciences/>
[2]: <https://medcitynews.com/2026/11/johnson-johnson-jnj-ollin-biosciences-acquisition-bispecific-antibody-vegf-ang2-wet-amd-dme/>
[3]: <https://www.pharmaceutical-technology.com/news/lilly-to-acquire-calytrix-bio-1-5bn/>
[4]: <https://www.pharmaceutical-technology.com/news/seawolf-sanofi-agree-drug-deal/>
[5]: <https://www.biocentury.com/article/661621/after-gene-therapy-setbacks-j-j-pays-2-2b-for-ollin-adds-retinal-disease-candidate?utm_source=bc_rss&utm_medium=rss>
[6]: <https://european-biotechnology.com/latest-news/cellectis-plans-70-workforce-cuts-sanofi-signs-1-2b-dna-medicines-deal-astrazeneca-buys-omniose/>
[7]: <https://www.pharmaceutical-technology.com/news/uk-biotech-sectors-calls-on-government-support-sector-scale/>
